Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25381300
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Neurology
2014 ; 83
(24
): 2239-46
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Treatment of sporadic inclusion body myositis with bimagrumab
#MMPMID25381300
Amato AA
; Sivakumar K
; Goyal N
; David WS
; Salajegheh M
; Praestgaard J
; Lach-Trifilieff E
; Trendelenburg AU
; Laurent D
; Glass DJ
; Roubenoff R
; Tseng BS
; Greenberg SA
Neurology
2014[Dec]; 83
(24
): 2239-46
PMID25381300
show ga
OBJECTIVE: To study activin signaling and its blockade in sporadic inclusion body
myositis (sIBM) through translational studies and a randomized controlled trial.
METHODS: We measured transforming growth factor ? signaling by SMAD2/3
phosphorylation in muscle biopsies of 50 patients with neuromuscular disease (17
with sIBM). We tested inhibition of activin receptors IIA and IIB (ActRII) in 14
patients with sIBM using one dose of bimagrumab (n = 11) or placebo (n = 3). The
primary outcome was the change in right thigh muscle volume by MRI at 8 weeks.
Lean body mass, strength, and function were secondary outcomes. Twelve of the
patients (10 bimagrumab, 2 placebo) participated in a subsequent 16-week
observation phase. RESULTS: Muscle SMAD2/3 phosphorylation was higher in sIBM
than in other muscle diseases studied (p = 0.003). Eight weeks after dosing, the
bimagrumab-treated patients increased thigh muscle volume (right leg +6.5%
compared with placebo, p = 0.024; left leg +7.6%, p = 0.009) and lean body mass
(+5.7% compared with placebo, p = 0.014). Subsequently, bimagrumab-treated
patients had improved 6-minute walking distance, which peaked at 16 weeks
(+14.6%, p = 0.008) compared with placebo. There were no serious adverse events;
the main adverse events with bimagrumab were mild acne and transient involuntary
muscle contractions. CONCLUSIONS: Transforming growth factor ? superfamily
signaling, at least through ActRII, is implicated in the pathophysiology of sIBM.
Inhibition of ActRII increased muscle mass and function in this pilot trial,
offering a potential novel treatment of sIBM. CLASSIFICATION OF EVIDENCE: This
study provides Class I evidence that for patients with inclusion body myositis,
bimagrumab increases thigh muscle volume at 8 weeks.
|Activin Receptors, Type II/antagonists & inhibitors
[MESH]
|Adult
[MESH]
|Aged
[MESH]
|Aged, 80 and over
[MESH]
|Antibodies, Blocking
[MESH]
|Antibodies, Monoclonal, Humanized
[MESH]
|Antibodies, Monoclonal/adverse effects/*therapeutic use
[MESH]
|Double-Blind Method
[MESH]
|Exercise Test
[MESH]
|Female
[MESH]
|Humans
[MESH]
|Immunologic Factors/adverse effects/*therapeutic use
[MESH]
free
free
free
